# Biotech Slices Data Post Hoc, Hopes FDA Doesn't Notice - Date: 2026-04-02 - Category: Biotech & Life Sciences Lipocine is betting that a post hoc subgroup of 54 responders is enough to win FDA approval for its oral PPD drug, even though the full trial failed. Whether regulators agree will decide whether the drug ever reaches patients. ---